AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- Researchers in Israel conducted a study of the "efficacy of oral tolerance with heat shock protein (HSP) 65 in two apparently nonoverlapping models of murine atherosclerosis."
Providing background information for their work, D. Harats and colleagues, Chaim Sheba Medical Center, Institute for Lipid and Atherosclerosis Research, noted several points:
* "Atherosclerosis is considered to be a chronic inflammatory process."
* "Autoimmune mechanisms have been shown to influence atherogenesis in experimental animal models."
* "Heat shock protein 65 is a candidate antigen thought to drive a proatherogenic immune-mediated response."
* "Mucosal tolerance is a therapeutic means of accomplishing immune unresponsiveness toward a given antigen by feeding it before active induction of the disorder."
In this study, "[l]ow-density lipoprotein receptor deficient mice were fed with different doses of HSP65 every other day for 10 days. Feeding with either bovine serum albumin (BSA) or phosphate buffered saline (PBS) served as control. One day after the last feeding, mice were challenged either by immunization with heat-killed Mycobacterium tuberculosis or by a high fat diet."